Browse News
Filter News
Found 172 articles
-
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
4/23/2024
INmune Bio, Inc. is delighted to announce the successful completion of the extended stability validation for XPro TM continuous storage in solution at 2-8C.
-
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
4/22/2024
INmune Bio, Inc. today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price.
-
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4/8/2024
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).
-
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
3/28/2024
INmune Bio Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its financial results for the year ended December 31, 2023 and provides a business update.
-
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
3/26/2024
INmune Bio Inc. (NASDAQ: INMB) (the “Company”) today announced that it will host a conference call on Thursday, March 28, 2024 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2023 and to provide a corporate update.
-
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
3/13/2024
INmune Bio Inc. announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy, which the organization considers its highest honor.
-
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
3/5/2024
INmune Bio, Inc., a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease reports significant improvements in electroencephalography, a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
-
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/12/2024
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) announced today that RJ Tesi, M.D., Chief Executive Officer, and David Moss, Chief Financial Officer, will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.
-
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
2/6/2024
INmune Bio, Inc. announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
-
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
1/30/2024
INmune Bio Inc., a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with XProTM, a dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company’s AD clinical trial program has been lifted.
-
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
1/2/2024
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, dosed the first patient in the Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC) on December 27, 2023.
-
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
12/18/2023
INmune Bio Inc. (NASDAQ: INMB) (the “Company”) is on track to complete enrollment of its Phase II clinical trial in patients with early Alzheimer’s Disease and biomarkers of inflammation in 2024.
-
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
11/29/2023
INmune Bio, Inc. is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2.
-
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
11/27/2023
INmune Bio, Inc. announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.
-
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
11/15/2023
INmune Bio, Inc. has received acceptance of a Clinical Trial Application (CTA) under EU Clinical Trials Regulation to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™ in Poland.
-
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
11/1/2023
INmune Bio Inc. announces its financial results for the quarter ended September 30, 2023 and provides a business update.
-
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
10/31/2023
INmune Bio, Inc. announced an update regarding the company’s patent covering its proprietary cell line, “INB16”.
-
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
10/30/2023
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer.
-
Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting
10/25/2023
Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the Clinical Trials on Alzheimer's Disease Annual Meeting on Wednesday October 25th in Boston, Massachusetts.
-
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
10/17/2023
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer’s Disease (CTAD) to be held October 24-27 in Boston, MA.